Mutation News and Research

RSS

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.

9 Aug 2010

New familial link in juvenile myelomonocytic leukemia discovered

A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML. The study demonstrates a new familial link in JMML and has significant implications, the researchers say, for improving the diagnosis and treatment of the disease.

9 Aug 2010

Response Genetics total revenue for second-quarter 2010 increases 197% to $5.6 million

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three and six months ended June 30, 2010.

7 Aug 2010

Scientists identify genetic variant that increases risk of schizophrenia

A group of scientists has identified a genetic variant that substantially increases the risk for developing schizophrenia in Ashkenazi Jewish and other populations. The study, published by Cell Press on August 5th in the American Journal of Human Genetics, associates a deletion on chromosome 3 with increased incidence of schizophrenia.

6 Aug 2010

Research on human disease origins to predict, prevent next outbreak

Most infectious diseases infect multiple host species, but to date, efforts to quantify the frequency and outcome of cross-species transmission (CST) of these diseases have been severely limited.This lack of information represents a major gap in knowledge of how diseases emerge, and from which species they will emerge.A paper published this week in the journal Science by a team of researchers led by Daniel Streicker of the University of Georgia has begun to close that gap.

6 Aug 2010

University of Pennsylvania announces recipients of 2010 Templeton Positive Neuroscience Awards

The Positive Psychology Center of the University of Pennsylvania and the John Templeton Foundation have announced the recipients of the 2010 Templeton Positive Neuroscience Awards, $2.9 million given to 15 new research projects at the intersection of neuroscience and positive psychology.

5 Aug 2010

ARIAD reports $159.3 million second-quarter net income

ARIAD Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2010 and provided an update on corporate developments.

5 Aug 2010

Infinity reports $18.4 million total revenue for second-quarter 2010

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today detailed recent developments in its product development portfolio and announced second quarter 2010 financial results.

4 Aug 2010

Researchers identify TACI; MyD88 activates immune system against infection

Researchers from Mount Sinai School of Medicine have found a new mechanism that explains how certain immune cells are activated to create protective antibodies against infections or pathological antibodies such as those present in autoimmune diseases like lupus and rheumatoid arthritis. The research is published online in the September issue of Nature Immunology.

4 Aug 2010

BCM collaborates with Roche NimbleGen for high throughput exome capture technology

The Baylor College of Medicine Human Genome Sequencing Center has standardized its target enrichment human disease research studies on Roche NimbleGen Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More than 15 different diseases will be investigated by Baylor HGSC, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the goal of better understanding causative mutations and their impact on these diseases.

4 Aug 2010

Body’s natural cell suicide program may trigger tumor development: Study

Cancer research springs a surprise. Researchers at Walter and Eliza Hall Institute in Melbourne have found that programmed cell death (apoptosis) or cell suicide plays a role in tumor development. This process is an important phenomenon in our body as it helps remove damaged cells. Now apoptosis has been found to be protective against cancer formation and autoimmune diseases.

1 Aug 2010

Study implicates Fritz's role in human genetic disorders

Mutations in a gene known as "Fritz" may be responsible for causing human genetic disorders such as Bardet-Biedl syndrome, University of Texas at Austin developmental biologist John Wallingford and Duke University human geneticist and cell biologist Nicholas Katsanis have found.

31 Jul 2010

Families with male breast cancer perceive as being at higher risk: Study

People with a family history of male breast cancer perceive themselves to be at higher risk of developing the disease than do patients with a family history of female breast cancer; however those with male breast cancer in their families are less likely to know about or seek genetic testing than those with a family history of female breast cancer, according to a study led by researchers at the University of Louisville's James Graham Brown Cancer Center.

30 Jul 2010

Researchers discover three disease-causing genes in Salmonella

Researchers have discovered a novel mechanism in Salmonella that affects its virulence and its susceptibility to antibiotics by changing its production of proteins in a previously unheard of manner. This allows Salmonella to selectively change its levels of certain proteins to respond to inhospitable conditions.

30 Jul 2010

Researchers identify genetic mutation for Uner Tan Syndrome

A team of researchers from leading universities in Turkey and the United States have reported that they have identified the genetic mutation responsible for the Uner Tan Syndrome (UTS) using advanced genetic capture and sequencing technologies from Roche. The combined genomic technologies enabled the team of scientists to identify the causative mutation of this debilitating disease after years of mystery.

30 Jul 2010

Researchers discover enzyme crucial for DNA repair

Researchers have discovered an enzyme crucial to a type of DNA repair that also causes resistance to a class of cancer drugs most commonly used against ovarian cancer.Scientists from The University of Texas MD Anderson Cancer Center and the Life Sciences Institute of Zhejiang University in China report the discovery of the enzyme and its role in repairing DNA damage called cross-linking in the Science Express advance online publication of Science.

30 Jul 2010

AVEO second-quarter total revenues increase to $15.6 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.

29 Jul 2010

Exact Sciences to demonstrate methylation specific technology at AACC annual meeting

Exact Sciences Corp. today announced that data being presented this afternoon at the annual meeting of the American Association of Clinical Chemistry demonstrates that its methylation specific technology, using a combination of DNA methylation markers, detected 100 percent of colorectal cancers and precancers at a specificity cutoff of 100 percent in a preliminary study with colorectal tissue.

29 Jul 2010

Scientists identify new targets to develop treatment for HD

Scientists at the Buck Institute for Age Research have discovered that a particular family of enzymes are involved in the breakdown of proteins that modify the production of toxic fragments that lead to the pathology of Huntington's disease. These enzymes, matrix metalloproteinases, provide new targets for drug therapies for the disease - targets that have already been shown to respond to cancer drugs currently in clinical development.

29 Jul 2010

Loss of key nerve cells cause Parkinson's disease: Research

Scientists at the Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson's disease. This discovery not only may explain how a genetic mutation linked to Parkinson's causes the cells' death, but could also open the door to new therapeutic approaches for the malady.

29 Jul 2010